@article{9a30525995bd49b595c9296f4f19c424,
title = "TRPC5 and the path towards analgesic drug development",
abstract = "A recent study by Sadler et al. highlights transient receptor potential canonical 5 (TRPC5) as a potential target for treating pain conditions. This article discusses their findings in the context of analgesic drug development, an urgent pursuit required to combat the opioid crisis and help millions of people with chronic pain.",
keywords = "chronic pain, lysophosphatidylcholine, reproducibility, Trp channels",
author = "Franziska Denk",
note = "Funding Information: F.D. has received funding through an MRC New Investigator Research Grant ( MR/P010814/1 ) and a Medical Research Foundation Prize ( MRF-160-0015-ELP-DENK-C0844 ). She thanks Dr David Andersson for his insightful comments on this manuscript. Funding Information: F.D. has received funding through an MRC New Investigator Research Grant (MR/P010814/1) and a Medical Research Foundation Prize (MRF-160-0015-ELP-DENK-C0844). She thanks Dr David Andersson for his insightful comments on this manuscript. F.D. is on the Scientific Advisory Board of the Swedish pharmaceutical company Cellectricon. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = sep,
doi = "10.1016/j.tins.2021.06.010",
language = "English",
volume = "44",
pages = "687--688",
journal = "Trends in Neurosciences",
issn = "0166-2236",
publisher = "Elsevier Limited",
number = "9",
}